Effect of meclofenamate on renal vascular resistance in early Goldblatt hypertension in conscious and anesthetized dog

Differential effect of a selective cyclooxygenase-2 inhibitor versus indomethacin on renal blood flow in conscious volume-depleted dogs

Renal effects of a selective cyclooxygenase-2 (COX-2) inhibitor [MF-Tricyclic; 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone] were studied in control and volume-depleted conscious dogs. MF-Tricyclic was compared with the nonselective COX-1/COX-2 inhibitor indomethacin. Six instrumented male dogs were randomly selected to receive MF-Tricyclic or indomethacin at 10 mg/kg. Volume depletion was effected by a sodium-restricted diet (14 days) with administration of furosemide (7.5 mg/kg, i.v.) the day before the experiment. Indomethacin ablated systemic COX-1 activity (p < 0.05), whereas MF-Tricyclic did not affect this activity. Each compound achieved plasma concentrations in excess of their respective median inhibitory concentrations (IC50 values) against canine COX-2. In controls, neither compound affected mean arterial pressure (MAP), heart rate (HR), renal blood flow (RBF), fractional excretion (FE) Na+, or FE K+. In volume-depleted dogs, indomethacin reduced RBF (p < 0.05), whereas MF-Tricyclic did not affect this parameter. Indices of renal function in volume-depleted dogs were not affected. These data are consistent with the view that the effects of indomethacin on RBF are a consequence of inhibition of COX-1 activity. Furthermore, in these studies, short-term administration of a selective COX-2 inhibitor was without deleterious effects on renal function.

Indomethacin decreases arterial blood pressure and plasma renin activity in rats with aortic ligation

Severe renovascular hypertension was produced in rats by complete aortic ligation between the origin of the renal arteries. Six days after coarctation, a carotid cannula was implanted and mean arterial blood pressure (MABP) and plasma renin activity (PRA) were determined. Subsequently, indomethacin (5 mg/kg in oil) or vehicle was administered subcutaneously three times in the following 24-hour period. On day 7, MABP and PRA were again determined. Indomethacin reduced MABP from 179.0 +/- 6.7 to 156.5 +/- 8.8 mm Hg (P less than 0.002, n = 11) and PRA from 21.2 +/- 7.3 to 9.3 +/- 2.9 ng AI/ml per hr (P less than 0.045, n = 10), whereas vehicle treatment did not alter either MABP or PRA (n = 6). There was a significant association between the decrease in MABP and the percentage decrease in PRA following indomethacin treatment (r = 0.766, P less than 0.016). A similar study was performed in aortic ligated rats in which the left kidney was removed at the time of ligation. In these animals, 6 days after surgery, MABP and PRA were 128.0 +/- 5.9 mm Hg and 0.11 +/- 0.06 ng AI/ml per hr (n = 6), respectively, and indomethacin had no effect on either MABP or PRA. These data provide evidence that the prostaglandin system is involved in the release of renin and in the pathogenesis of elevated blood pressure in this model of renin-dependent hypertension.

Sympathetic and renin-angiotensin system influence on blood pressure and renal blood flow of two-kidney, one clip Goldblatt hypertensive dog

Conscious normotensive and two-kidney, one clip Goldblatt hypertensive dogs were studied to determine the influence of the sympathetic and renin-angiotensin systems on the blood pressure and renal blood flow. Renal blood flow was monitored in a single kidney of the normotensive dogs and in the contralateral kidney of the hypertensive dogs. Saralasin was infused intravenously (i.v.) at 1 microgram/kg/min for 15 minutes in untreated and guanethidine-treated animals. Guanethidine (i.v.) decreased blood pressure (BP) in the hypertensives at X = 16 days after Goldblatt clamp application, but not in the normotensives, and did not affect renal blood flow or vascular resistance in either group. Saralasin produced approximately the same BP decrease in both untreated and guanethidine-treated hypertensives at X = 12 days after Goldblatt clamp application; the combined effect of the drugs was greater than saralasin alone. Blood flow and vascular resistance of the hypertensives' contralateral kidney were not significantly affected by saralasin in these experiments. No sustained effect on BP or renal blood flow was obtained with saralasin in the normotensives. Administration of furosemide was utilized to increase plasma renin activity (PRA) in another series of experiments. In both normotensives and hypertensives, PRA was elevated at 2-3 hours after furosemide application, being greater in the hypertensives. When the renin-angiotensin system was activated in this manner, saralasin had a significant hypotensive and renal vasodilator effect in the hypertensives, but not in the normotensives.